{"organizations": [], "uuid": "61505a585bef677f967565d8d45eff86e6eb4555", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-juniper-pharmaceuticals-qtrly-basi/brief-juniper-pharmaceuticals-qtrly-basic-eps-0-11-idUSASB0C9FR", "country": "US", "domain_rank": 408, "title": "BRIEF-Juniper Pharmaceuticals Qtrly Basic EPS $0.11", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-03-08T21:08:00.000+02:00", "replies_count": 0, "uuid": "61505a585bef677f967565d8d45eff86e6eb4555"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-juniper-pharmaceuticals-qtrly-basi/brief-juniper-pharmaceuticals-qtrly-basic-eps-0-11-idUSASB0C9FR", "ord_in_thread": 0, "title": "BRIEF-Juniper Pharmaceuticals Qtrly Basic EPS $0.11", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "juniper pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Juniper Pharmaceuticals Inc:\n* JUNIPER PHARMACEUTICALS REPORTS FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS\n* JUNIPER PHARMACEUTICALS INC - QTRLY BASIC EARNINGS PER SHARE $0.11\n* JUNIPER PHARMACEUTICALS INC - QTRLY REVENUE $11.8 MILLION VERSUS $20.9 MILLION\n* JUNIPER PHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS WERE $21.4 MILLION AS OF DECEMBER 31, 2017\n* JUNIPER PHARMACEUTICALS - BELIEVES CURRENT CASH AND CASH EQUIVALENTS, CASH FROM OPERATIONS, WILL BE SUFFICIENT FOR AT LEAST NEXT TWELVE MONTHS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T21:08:00.000+02:00", "crawled": "2018-03-09T14:39:59.000+02:00", "highlightTitle": ""}